Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited EBIT for the year ending March 31, 2024: USD 75.08 M

Piramal Pharma Limited EBIT is USD 75.08 M for the year ending March 31, 2024, a 263.71% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Piramal Pharma Limited EBIT for the year ending March 31, 2023 was USD 20.64 M, a -74.89% change year over year.
Piramal Pharma Limited EBIT for the year ending March 31, 2022 was USD 82.21 M, a 9.37% change year over year.
Piramal Pharma Limited EBIT for the year ending March 31, 2021 was USD 75.17 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years